[Biomarkers in breast cancer with high over-expression of HER2 protein].
The predictive value of the HER2 protein over-expression in order to the breast carcinomas response to dexorubicin and Herceptin therapy has been proved. DAKO Herceptest pretend to be a tool in the identification of patients for whose Herceptin might be an option. In one breast carcinoma serie studied in our laboratory we detected a high over-expression of HER2. Only four cases were recurrent tumors. To characterize the breast carcinoma serie assayed with DAKO Herceptest by the expression of other prognostic or predictive markers (hormone receptors, Ki-67, p53, tumoral ploidy) that are routinely tested in our laboratory. 97 consecutive mammary carcinomas recieved between July and October, 2000 in the ABC Medical Center's Surgical Pathology Department of Mexico City, were analyzed with DAKO Herceptest, and for estrogen/progesterone receptors, p53, Ki-67 and tumoral ploidy. We found HER2 over-expression in 46.3% of the cases tested. The 47.6% of this subgroup showed hormone receptors negative immunophenotype, 89.7% high cellular proliferation index (Ki-67), 72.5% of p53 expression, and tumoral aneuploidy in 72.9%. The high expression of desfavorable prognostic and/or predictive factors for mammary carcinomas in the casuistic, suggest that the population in study have a particularly aggressive phenotype, where the over-expression of HER2 protein results in concordance and it is not related with tumoral relapse.